4157.TWO

TaiGen Biopharmaceuticals Holdings Limited [4157.TWO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

4157.TWO Stock Summary

Top 10 Correlated ETFs

4157.TWO

Top 10 Correlated Stocks

4157.TWO

In the News

4157.TWO Financial details

Company Rating
-
Market Cap
10.73B
Income
136.88M
Revenue
123.13M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
52
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-80.46
Forward P/E
-
PEG
5.09
P/S
91.18
P/B
14.23
P/C
-
P/FCF
-62.66
Quick Ratio
16.76
Current Ratio
17.5
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.19
EPS next Y
-
EPS next Q
-
EPS this Y
-157.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
43.39%
Revenue Q/Q
-7.72%
EPS Q/Q
-2284.87%
-
-
-
-
SMA20
-13.44%
SMA50
-18.51%
SMA100
-22.2%
Inst Own
-
Inst Trans
-
ROA
-16%
ROE
-17%
ROC
-0.15%
Gross Margin
91%
Oper. Margin
-123%
Profit Margin
-135%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
13.85-18.75
52W High
-44.44%
52W Low
-23.08%
RSI
51.66
Rel Volume
0.68
Avg Volume
1.39M
Volume
945.7K
Perf Week
8.46%
Perf Month
-10.31%
Perf Quarter
-27.8%
Perf Half Y
-29.08%
-
-
-
-
Beta
0.779
-
-
Volatility
0.24%, 0.9%
Prev Close
0%
Price
10
Change
0.1%

Something similar

Top by Market Cap
BRYN.DE
FXAIX
VTSAX
FB2A.DE
GOOGL
Top Correlated ETFs
CNUA.DE
WLDL.L
LGGG.L
GGRP.L
ISWD.L
Top Correlated Stocks
1325.TW
1760.TW
1762.TW
1802.TW
2312.TW
Similar Market Cap
JINDALPHOT.NS
603977.SS
CORRX
002434.SZ
0327.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 1.39M
  • Market Capitalization 10.73B
  • Employee 52
  • CEO Mr. Kuo-Lung Huang
  • Headquarters Taipei,TW
  • IPO Date 2013-08-30
  • Website https://www.taigenbiotech.com.tw

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.